Related references
Note: Only part of the references are listed.Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
N. Penel et al.
ANNALS OF ONCOLOGY (2011)
Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
M. S. Marcolino et al.
ANNALS OF ONCOLOGY (2011)
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature
Anat Gafter-Gvili et al.
LEUKEMIA RESEARCH (2010)
Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec™)
Jessica K. Gordon et al.
LEUKEMIA RESEARCH (2010)
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
Brian B. Hasinoff et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
Relationship of Ethnic Origin, Gender, and Age to Blood Creatine Kinase Levels
Ryan C. Neal et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib
Anna Franceschino et al.
HAEMATOLOGICA (2008)
O-Mel-Inib: A Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
Nicolas Penel et al.
INVESTIGATIONAL NEW DRUGS (2008)
Imatinib as a possible cause of severe rhabdomyolysis
Nicolas Penel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp
Bernd Kasper et al.
ANTI-CANCER DRUGS (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Serum creatine kinase levels and renal function measures in exertional muscle damage
PM Clarkson et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2006)
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands:: Report of two successfully treated cases
JC Alcedo et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2004)
US Food and Drug Administration drug approval summaries: Imatinib mesylate, mesna tablets, and zoledronic acid
MH Cohen et al.
ONCOLOGIST (2002)
Share Paper
